Original Article
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
N Engl J Med 2008; 358:2667-2677June 19, 2008
- Abstract
Background
It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied.
Methods
We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation. The primary outcome was the time to death from cardiovascular causes.
Results
A total of 1376 patients were enrolled (682 in the rhythm-control group and 694 in the rate-control group) and were followed for a mean of 37 months. Of these patients, 182 (27%) in the rhythm-control group died from cardiovascular causes, as compared with 175 (25%) in the rate-control group (hazard ratio in the rhythm-control group, 1.06; 95% confidence interval, 0.86 to 1.30; P=0.59 by the log-rank test). Secondary outcomes were similar in the two groups, including death from any cause (32% in the rhythm-control group and 33% in the rate-control group), stroke (3% and 4%, respectively), worsening heart failure (28% and 31%), and the composite of death from cardiovascular causes, stroke, or worsening heart failure (43% and 46%). There were also no significant differences favoring either strategy in any predefined subgroup.
Conclusions
In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy. (ClinicalTrials.gov number, NCT00597077.)
Media in This Article
Figure 1
Prevalence of Atrial Fibrillation at Each Follow-up Visit and between Visits.Figure 2
Kaplan–Meier Estimates of Death from Cardiovascular Causes (Primary Outcome).Article Activity
- Article
Atrial fibrillation and congestive heart failure are common cardiac disorders associated with substantial morbidity and mortality.1-7 Atrial fibrillation can lead to heart failure, and heart failure can lead to atrial fibrillation, which is present in 10 to 50% of patients with heart failure.8-14 An excessive ventricular rate, a loss of atrial contraction, and an irregular ventricular filling time that is associated with atrial fibrillation may all have negative clinical consequences in patients with heart failure. Most of the available evidence suggests that such patients with atrial fibrillation have a worse prognosis than those in whom sinus rhythm is maintained and that the presence of atrial fibrillation is an independent risk factor for death.8,9,11,14-20
The treatment of patients with heart failure and atrial fibrillation presents specific challenges. In view of the prognostic importance of atrial fibrillation in patients with heart failure, the restoration and maintenance of sinus rhythm with electrical cardioversion and antiarrhythmic drugs are often attempted.5,21-24 However, patients with impaired left ventricular function have an increased risk of adverse effects from antiarrhythmic drugs.25-27 Data from six trials do not support a routine strategy of rhythm control in patients with atrial fibrillation.28-33 However, only a small minority of patients who were enrolled in these trials had left ventricular dysfunction, and the lack of benefit from the maintenance of sinus rhythm in such patients may not apply to the general population of patients with heart failure.34
We wanted to determine, in an adequately powered, prospective clinical trial, whether the prevention of atrial fibrillation would improve survival in patients with heart failure. Therefore, we conducted a multicenter, prospective, randomized trial to test the hypothesis that a rhythm-control strategy would reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy, among patients with atrial fibrillation and congestive heart failure.
Methods
Study Design
The details of the protocol have been reported previously.15 The Atrial Fibrillation and Congestive Heart Failure trial was conducted in 123 centers in Canada, United States, Brazil, Argentina, Europe, and Israel. The institutional review board at each center approved the study, and all patients gave written informed consent. Recruitment began in May 2001 and was concluded in June 2005; the follow-up period ended on June 30, 2007. The steering committee designed the study. Data management and analyses were performed at the Montreal Heart Institute Coordinating Center. All authors reviewed and edited the manuscript and vouch for the completeness and accuracy of the data.
All patients purchased their own cardiac medications, except in cases of inadequate financial resources. In these cases, the manufacturers provided the medications at no cost to the patients.
Patients
To be eligible, patients had to meet all of the following criteria: a left ventricular ejection fraction of 35% or less, as measured by nuclear imaging, echocardiography, or cardiac angiography, with testing performed 6 months or less before enrollment; a history of congestive heart failure, which was defined as symptomatic New York Heart Association (NYHA) class II or IV heart failure within the previous 6 months, an asymptomatic condition for which the patient had been hospitalized for heart failure during the previous 6 months, or a left ventricular ejection fraction of 25% or less; a history of atrial fibrillation (with electrocardiographic documentation), which was defined as one episode lasting for at least 6 hours or requiring cardioversion within the previous 6 months or an episode lasting for at least 10 minutes within the previous 6 months and previous electrical cardioversion for atrial fibrillation; and eligibility for long-term therapy in either of the two study groups.
Exclusion criteria were persistent atrial fibrillation for more than 12 months, a reversible cause of atrial fibrillation or heart failure, decompensated heart failure within 48 hours before intended randomization, the use of antiarrhythmic drugs for other arrhythmias, second-degree or third-degree atrioventricular block (bradycardia of <50 beats per minute), a history of the long-QT syndrome, previous ablation of an atrioventricular node, anticipated cardiac transplantation within 6 months, renal failure requiring dialysis, lack of birth control in women of child-bearing potential, an estimated life expectancy of less than 1 year, and an age of less than 18 years.
Patients were randomly assigned to either the rhythm-control group or the rate-control group in an unblinded fashion. Randomization was performed with permuted blocks of various sizes and was stratified according to the study center.
Therapies
Rhythm Control
Aggressive therapy to prevent atrial fibrillation was recommended for patients in the rhythm-control group. Electrical cardioversion was recommended within 6 weeks after randomization in patients who did not have conversion to sinus rhythm after antiarrhythmic drug therapy. If necessary, a second cardioversion was recommended within 3 months after enrollment. Additional cardioversions were recommended for subsequent recurrences of atrial fibrillation. Amiodarone was the drug of choice for the maintenance of sinus rhythm, and either sotalol or dofetilide was used if required. 15 The installation of a permanent pacemaker was recommended if bradycardia prevented the use of antiarrhythmic drugs. Patients who did not have a response to antiarrhythmic drug therapy could be referred for nonpharmacologic therapy.
Rate Control
Therapies for rate control included adjusted doses of beta-blockers with digitalis to achieve the targeted heart rate, which was defined as a ventricular rate of less than 80 beats per minute during resting 12-lead electrocardiography and of less than 110 beats per minute during a 6-minute walk test; both tests were performed at 4 and 12 months and yearly thereafter. Atrioventricular nodal ablation and pacemaker therapy were recommended for patients who did not meet the rate-control targets with drug therapy.
Therapies for Heart Failure
Treatment with an angiotensin-converting–enzyme inhibitor or an angiotensin-receptor antagonist was recommended for all patients. Maximum tolerated doses of beta-blockers were recommended for patients in both groups. Anticoagulation was recommended for all patients.35 The use of an implantable defibrillator and ventricular-resynchronization therapy was recommended according to guidelines reported previously.36
Primary and Secondary Outcomes
Patients were evaluated at 3 weeks, at 4 months and every 4 months thereafter until 48 months, and subsequently every 6 months. The primary outcome was death from cardiovascular causes. Secondary outcomes were death from any cause, stroke, worsening congestive heart failure, hospitalization, quality of life, cost of therapy, and a composite of death from cardiovascular causes, stroke, or worsening congestive heart failure. Major clinical events were adjudicated by an events committee whose members were unaware of the patients' study-group assignments.
Statistical Analysis
Prespecified analyses were performed according to the intention-to-treat principle. Event rates for death from cardiovascular causes and secondary outcomes were estimated by the Kaplan–Meier method and compared by the log-rank test. The primary analysis was adjusted for the following baseline variables: age, sex, left ventricular ejection fraction, NYHA functional class, the presence or absence of diabetes or hypertension, the use or nonuse of an internal defibrillator, the time since the diagnosis of atrial fibrillation, the creatinine level, and the use or nonuse of a beta-blocker, angiotensin-converting–enzyme inhibitor, or oral anticoagulant. The level of statistical significance that was required for the primary analysis was adjusted to account for six interim analyses, each performed at an alpha level of 0.00014, resulting in a final significance level of 0.04998. Follow-up data were censored at the time of the patient's last contact with a study investigator or withdrawal from the study or, if the patient underwent heart transplantation, at the time of surgery. Univariate and multivariate Cox logistic-regression models were used to generate hazard ratios. All reported P values are two-tailed. A data and safety monitoring board reviewed the study twice yearly.
The original estimate that 1450 patients would be needed for the study was based on a 2-year rate of death from cardiovascular causes of 19% in the rate-control group, a power of 80% to detect a reduction of 25% in the rate of death from cardiovascular causes in the rhythm-control group, an accrual period of 2 years, a total study duration of 4 years, a rate of loss to follow-up of 2% per year, and a two-sided alpha level of 0.05.15 As a result of the extended period of recruitment, sample-size calculations were revised in 2005. It was estimated that with the increased follow-up time, 1374 patients would be needed to demonstrate with equal statistical power the same reduction in the number of deaths from cardiovascular causes.
Results
Patients
A total of 1376 patients were enrolled: 557 (40%) in Canada, 123 (9%) in the United States, 453 (33%) in Brazil and Argentina, 166 (12%) in Europe, and 77 (6%) in Israel (Figure 1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org). Of these patients, 682 were assigned to the rhythm-control group, and 694 were assigned to the rate-control group; 647 (95%) in the rhythm-control group and 650 (94%) in the rate-control group either completed follow-up or died. The mean (±SD) follow-up was 37±19 months; the longest period of follow-up was 74 months, and the median follow-up for all surviving patients was 47 months.
Baseline Characteristics
The two groups were generally well matched with respect to baseline characteristics (Table 1Table 1
Baseline Characteristics of the Patients.). Overall, the mean age was 67 years, and 82% of the patients were men. Thirty-one percent of the patients were in NYHA class III or IV, and coronary artery disease was the predominant cardiac diagnosis in 48% of the patients; 48% had systemic hypertension, and 21% had diabetes. The mean left ventricular ejection fraction was 27±6%. More than two thirds of the patients had persistent atrial fibrillation, and more than 50% had previously been hospitalized for atrial fibrillation or heart failure.Therapy
At 12 months of follow-up, 82% of patients in the rhythm-control group were receiving amiodarone (Table 2Table 2
Medical Therapy at 12 Months.). That percentage dropped to 76% at 24 months and to 73% at 36 months. A higher proportion of patients in the rate-control group than in the rhythm-control group received beta-blockers and digoxin. More than 90% of the patients were treated with an angiotensin-converting–enzyme inhibitor or an angiotensin-receptor blocker, and 90% received an oral anticoagulant.During the study, 142 patients (21%) in the rhythm-control group crossed over to the rate-control group. The most common reason for the switch was an inability to maintain sinus rhythm. Of the 66 patients (10%) in the rate-control group who crossed over to the rhythm-control group, the most common reason was worsening heart failure.
As documented on 12-lead electrocardiography, the prevalence of atrial fibrillation in the rhythm-control group was 54% at baseline and then declined to 33% at 3 weeks and to 17% at 4 months (Figure 1AFigure 1
Prevalence of Atrial Fibrillation at Each Follow-up Visit and between Visits.). The rate remained under 20% until the 24-month visit and was 27% at 4 years of follow-up. In the rate-control group, the prevalence of atrial fibrillation ranged from 59 to 70% during follow-up. The proportion of patients in whom electrocardiographically confirmed atrial fibrillation occurred between visits, as documented through chart review, paralleled trends documented on electrocardiography performed at scheduled visits (Figure 1B). During follow-up, 58% of patients in the rhythm-control group had at least one recurrence of atrial fibrillation.In the rate-control group, the baseline ventricular rate was within the range specified by the guidelines in 72% of patients who underwent a 6-minute walk test, and targets for the management of atrial fibrillation and for heart rate were subsequently achieved in 82 to 88% of patients during the first 3 years of follow-up.
Primary Outcome
The mean actuarial annual rate of death from cardiovascular causes for all patients was 8%. Death from cardiovascular causes, the primary outcome, occurred in 182 patients (27%) in the rhythm-control group and 175 patients (25%) in the rate-control group (Figure 2Figure 2
Kaplan–Meier Estimates of Death from Cardiovascular Causes (Primary Outcome).). The two curves overlapped throughout the study (P=0.59 by the log-rank test). The unadjusted hazard ratio for the rhythm-control group, as compared with the rate-control group, was 1.06 (95% confidence interval [CI], 0.86 to 1.30). This confidence interval was consistent with a maximum reduction of 14% and a maximum increase of 30% in the primary outcome in the rhythm-control group. After adjustment for baseline measures, the hazard ratio was 1.05 (95% CI, 0.85 to 1.29; P=0.67).Secondary Outcomes
Overall, 445 patients (32%) died during the study, at a rate of nearly 10% per year. Of these deaths, 80% were from cardiovascular causes (Table 3Table 3
Cause of Death.). Overall survival and the risks of stroke, worsening heart failure, and the composite of death from cardiovascular causes, stroke, or worsening heart failure were similar in the two groups (Figure 3Figure 3
Kaplan–Meier Estimates of Secondary Outcomes.).Hospitalizations, Procedures, and Other Events
The proportion of patients who required hospitalization was higher in the rhythm-control group than in the rate-control group (64% vs. 59%, P=0.06), particularly during the first year (46% vs. 39%, P=0.001). Also more frequent in the rhythm-control group were hospitalization for atrial fibrillation (14% vs. 9%, P=0.001) and hospitalization for bradyarrhythmia (6% vs. 3%, P=0.02) (Table A in the Supplementary Appendix). A higher proportion of patients in the rhythm-control than in the rate-control group required electrical cardioversion (59% vs. 9%, P<0.001). The rates of sustained ventricular tachyarrhythmias and major hemorrhage that did not involve the central nervous system were similar in the two groups (Table B in the Supplementary Appendix). No significant differences favoring either strategy were noted in any of 10 prespecified subgroups (Figure 2 in the Supplementary Appendix).
Discussion
In this multicenter, randomized trial involving patients with atrial fibrillation and congestive heart failure, the routine use of a rhythm-control strategy did not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy. In addition, there was no evidence of a reduction in the rate of death from cardiovascular causes in key prespecified subgroups, and there were no significant differences in important secondary outcomes (death from any cause, worsening heart failure, or stroke).
The study population is representative of an international population of patients with atrial fibrillation and congestive heart failure. Compliance with the assigned therapeutic strategy was high, and 75 to 80% of patients in the rhythm-control group were in sinus rhythm at repeated assessments during a relatively long follow-up period (3 years on average).
The importance of this trial is that it compared a rhythm-control strategy with a rate-control strategy specifically in patients with heart failure. Our findings are consistent with studies that did not show a benefit of rhythm control on mortality or morbidity in patients with atrial fibrillation, most of whom did not have heart failure.28-33 As compared with some previous trials involving patients who had atrial fibrillation without heart failure,30,31 our study showed no trend toward an increased rate of death or stroke associated with rhythm control, possibly because we excluded patients who were using class I antiarrhythmic agents and because our patients had a higher rate of use of warfarin than those in the previous trials.
Our results cannot be generalized to patients with heart failure and preserved left ventricular function. Atrial fibrillation is common in such patients, particularly in the elderly, but little is known about the prognostic effect and treatment of atrial fibrillation in patients who have heart failure with preserved systolic function.20,37 The therapies we used to maintain sinus rhythm were predominantly pharmacologic, which reflects current general practice for patients with heart failure. Although some data suggest that ablation can improve ventricular function in patients with abnormal systolic function,38,39 the effects of these procedures on ventricular function and outcome in patients with heart failure remain to be established in prospective, randomized clinical trials.
In our study, the actuarial annual rate of death (10%) was somewhat higher than the rate that has been reported in contemporary trials involving patients with heart failure. In the Sudden Cardiac Death in Heart Failure trial (ClinicalTrials.gov number, NCT00000609), which enrolled patients similar to those in our trial with respect to left ventricular dysfunction, the annual mortality was approximately 9% for medically treated patients and 7% for those who received an implantable defibrillator.40 However, in that trial, the average age of the patients was 60 years, and only 15% had a history of atrial fibrillation, as compared with our trial, in which the average age was 67 years and all patients had atrial fibrillation. The proportion of patients with implantable defibrillators was low in our trial (7% of patients at baseline and an additional 9% during follow-up), reflecting international practice over the course of the trial, and 36% of all deaths were presumed to be associated with arrhythmia. Therefore, wider use of implantable defibrillators might have decreased the mortality in our study.
Patients in the rhythm-control group were more likely to be hospitalized than were those in the rate-control group, particularly during the first year after enrollment. This finding probably reflects the need for repeated cardioversion and adjustment of antiarrhythmic therapy, which is consistent with the results of previous studies.28,30,32
Several factors may explain why the rhythm-control strategy did not reduce mortality among patients with heart failure. The predictive value of atrial fibrillation in patients with heart failure may be due to the negative prognostic features that make atrial fibrillation more likely (e.g., worse ventricular function, increased neurohormonal activation, and the presence of an underlying inflammatory state) rather than an independent effect of atrial fibrillation on the outcome. Although most patients in the rhythm-control group were free of atrial fibrillation at repeated assessments, not all patients were in sinus rhythm at all times. In addition, some patients in the rate-control group were free of atrial fibrillation during follow-up. If atrial fibrillation has a truly independent effect on prognosis, then a greater decrease in the prevalence of atrial fibrillation may be needed to show a reduction in mortality. Finally, the potential benefit of sinus-rhythm maintenance with respect to mortality may have been neutralized by harmful effects of currently available antiarrhythmic therapies.
Our clinical trial provided important new information concerning two widely used treatment strategies for atrial fibrillation in patients with heart failure. The study hypothesis was not borne out, and none of the postulated benefits of a rhythm-control strategy were confirmed. The rate-control strategy eliminated the need for repeated cardioversion and reduced rates of hospitalization. In conclusion, our results suggest that rate control should be considered a primary approach for patients with atrial fibrillation and congestive heart failure.
Supported by a grant (MCT-41552) from the Canadian Institutes of Health Research.
Dr. Roy reports receiving consulting fees from Cryocath, Astellas, Cardiome, and Sanofi-Aventis and lecture fees from Astellas, Cardiome, and Sanofi-Aventis; Dr. Talajic, consulting fees from Medtronic and Boehringer Ingelheim and grant support from Boehringer Ingelheim, Bristol-Myers Squibb, Servier, Medtronic, Sanofi-Aventis, and Johnson & Johnson; Dr. Nattel, consulting fees from Xention, AstraZeneca, and Nissan Chemical and grant support from Xention, LAB Pharmaceuticals, and Devgen; Dr. Wyse, consulting fees from Novartis, Boehringer Ingelheim, Astellas, Medtronic, Sanofi-Aventis, Bristol-Myers Squibb, and Biotronik and lecture fees from Astellas; Dr. Arnold, advisory-board fees from Novartis, Sanofi-Aventis, GlaxoSmithKline, and Medtronic and grant support from Novartis, Boehringer Ingelheim, Atherogenics, Vasogen, Merck, and Integrium; Dr. Camm, consulting fees from Sanofi-Aventis, Cardiome, and Astellas and lecture fees from Sanofi-Aventis and Cardiome; Dr. Hohnloser, consulting and lecture fees from Sanofi-Aventis, St. Jude, and Procter & Gamble and lecture fees from Boehringer Ingelheim; Dr. Pedersen, consulting fees from Sanofi-Aventis; Dr. W.G. Stevenson, consulting fees from Biosense Webster and lecture fees from Medtronic, St. Jude Medical, and Boston Scientific; and Dr. Waldo, consulting fees from GlaxoSmithKline, Cryocor, Reliant, Sanofi-Aventis, Biosense Webster, Biotronik, St. Jude Medical, Astellas, and Solvay, lecture fees from Reliant and Sanofi-Aventis, and grant support from Boehringer Ingelheim and Cardax. No other potential conflict of interest relevant to this article was reported.
We thank our patients who made this study possible; Crystaal, Merck Frosst, and Sanofi-Aventis for providing bisoprolol, enalapril, and amiodarone, respectively, to patients without medical insurance; and Medtronic Canada for providing pacemaker rebates.
Source Information
From the Montreal Heart Institute and the Université de Montréal, Montreal (D.R., M.T., S.N., M.G.B., M.D., A.D., P.G.G., J.L., J.-L.R., B.T.); Libin Cardiovascular Institute, Calgary, AB, Canada (D.G.W.); St. Michael's Hospital, Toronto (P.D.); Duke University Medical Center, Durham, NC (K.L.L.); London Health Sciences Center, London, ON, Canada (J.M.O.A.); Rhode Island Hospital–Lifespan Academic Center, Providence, RI (A.E.B.); St. George's Hospital Medical Center, London (A.J.C.); Population Health Research Institute, Hamilton, ON, Canada (S.J.C.); J.W. Goethe University, Frankfurt, Germany (S.H.H.); Hôpital Européen Georges Pompidou, Paris (J.-Y.L.H.); Institut de Cardiologie de Québec, QC, Canada (G.O.); Bispebjerg University Hospital, Copenhagen (O.D.P.); Veterans Affairs Medical Center–West Los Angeles, Los Angeles (B.N.S.); Brigham and Women's Hospital, Boston (L.W.S., W.G.S.); and University Hospitals Case Medical Center, Cleveland (A.L.W.).
Address reprint requests to Dr. Roy at the Montreal Heart Institute, 5000 Belanger St., Montreal, QC H1T 1C8, Canada, or at d_roy@icm-mhi.com.
Investigators and committees in the Atrial Fibrillation and Congestive Heart Failure trial are listed in the Appendix.
Appendix
The following persons participated in this trial: Executive Committee: D. Roy (chair), M. Talajic, S. Nattel, D.G. Wyse, P. Dorian, M.G. Bourassa, J. Lambert, J.L.Rouleau; Steering Committee: J.M.O. Arnold, A.E. Buxton, A.J. Camm, S.S. Connolly, M. Dubuc, A. Ducharme, P.G. Guerra, S. Hohnloser, J.Y. Le Heuzey, K.L. Lee, G. O'Hara, O.D. Pedersen, I. Schmid, B.N. Singh, L.W. Stevenson, W.G. Stevenson, B. Thibault, A.L. Waldo; Data and Safety Monitoring Board: G. Dagenais (chair), D. Johnstone, R. Nadeau, R. Roberts, D. Roden, S. Shapiro, D.P. Zipes; External Events Committee: N. Racine (chair), J. Brophy, I. Dyrda, L.-H. Lebrun, G. Lalonde, A. Roussin, M. Sturmer; Montreal Heart Institute Coordinating Center: D. Johnson (director), M.C. Guertin (biostatistician). S. Levesque, C. Alcide, F. Desgagné, M.C. Tremblay; Study Management: M. Morello (coordinator), C. Bossy, M. Provencher; Investigators: Argentina — Instituto Argentino de Diagnostico y Tratamiento: J. Gonzalez-Zuelgaray; Centre Privado de Cardiologia de Tucuman: L. Aguinaga; Instituto de Cardiologia de Corrientes: D.L. Pozzer; Hospital General de Agudos J.M. Mejia: M.V. Elizari, J. Galperin; Clinica y Maternidad Sulzo Argentina: S. Dubner; Sanatorio Britannico Rosario: R. Lanzotti; Fundacion Rusculleda: J.L. Serra; Instituto Modelo de Cardiologia: D. Boccardo; Instituto Cardiovascular de Buenos Aires: A. Giniger; Hospital Privado–Centro Médico de Cordoba: A. Caeiro; Sanatorio Guemes: A. Peralta, B. Sansalone. Belgium — Clinique Sud Luxembourg: G.H. Mairesse; Cliniques Universitaires UCL de Mont-Godinne: L. De Roy. Brazil — Hospital São Lucas Da Pontificia Universidade Católica do Rio Grande do Sul: C. Kalil; Hospital Italiano de Garibaldi: J.L. Ramos; Instituto de Cardiologia DO RS: G. Glotz De Lima; Instituto de Molestias Cardiovasculares: A. Menezes Lorga; Hospital Pro-Cardiaco: E.T. Mesquita; Barra d'Or Hospital: O. Ferreira de Souza; Hospital da PUC–Curitiba: J.C. Moura Jorge; Hospital de Clinicas de Porto Alegre: L. Zimerman; Federal University of Sao Paulo: A.A.V. de Paola. Canada — Institut de Cardiologie de Montréal: D. Roy; Institut de Cardiologie de Québec: G. O'Hara; Port Arthur Clinic: F. Nigro; Recherche Medicale St-Jérôme: D. Ouimet; Libin Cardiovascular Institute of Alberta: D.G. Wyse; Hamilton General Hospital: C. Demers; Cité de La Santé de Laval: H. Mayrand; London Health Sciences Centre: J.M.O. Arnold; CH Pierre Le Gardeur: G. Gosselin; Keary Medical Centre: D. Rupka; Centre Hospitalier de l'Université de Montréal (CHUM)–Notre-Dame: B. Coutu; Centre Universitaire de Santé McGill (CUSM)–Hôpital Général de Montréal: T. Huynh; Hôtel-Dieu de Lévis: F. Delage; Queen Elizabeth II Health Centre: J. Sapp; St. Michael's Hospital: P. Dorian; CHUM–Hôtel-Dieu: P. Costi; C.H. de la Sagamie: G. Tremblay; Sunnybrook and Women's College Health Sciences Centre: C. Joyner; Hôpital du Sacré-Cœur de Montréal: T. Kus; Cambridge General Hospital: S. Vizel; C.H. Régional de Rimouski: N. Dionne; Centre Hospitalier Universitaire de Sherbrooke Fleurimont: R. Harvey; Victoria Heart Institute: L. Sterns; Halton Heart Institute: T. Vakani; University of Alberta: S. Kimber, K. Kavanagh; Curans Medical Research: C. Lai; CUSM–Hôpital Royal Victoria: N. Giannetti; C.H. Régional de Lanaudière: S. Kouz; CHUM–St. Luc: M. Ruel; C.H. Régional de Trois-Rivières: M. Garand; London Health Sciences Centre: S. Connors; Midtown Medical Centre: S. Bose; Baywood Medical Centre: R. Leader; Brampton Research Associates: D. Borts; Ottawa Heart Institute: D. Birnie; Hôpital Maisonneuve-Rosemont: C. Constance; Centre de Santé et de Services Sociaux de Beauce: D. Dion; Hôpital du Haut-Richelieu: D. Gossard; Royal University Hospital: R. Rajakumar; Lakeshore General Hospital: F. Sandrin; C.H. Honoré-Mercier: D. Grandmont; Centre Hospitalier Universitaire de Québec Cardiologie: M. Samson; Hôpital Général Juif: C. Michel; L. Dumont Regional: R. Lee; Vancouver General Hospital: V. Bernstein; Midtown Medical Centre: N. Sharma; Surrey Memorial Hospital: R. Dong; Grey Nuns Community Hospital and Health Centre: M. Senaratne; Toronto General Hospital: D. Ing; Newmarket Cardiology Research Group: Z. Wulffhart; Medecine Hat Medical Centre: M. Weigel; St. Paul's Hospital: C. Kerr; Scarborough Hospital: T. Davies. Denmark — Glostrup University Hospital: J. Rokkedal Nielson; Esbjerg Centralsygehus: H.B. Andersen; Viborg Sygehus: H. Bagger, O.L. Pedersen; Amager Hospital: H. Nielsen. J.B. Schou; Gentofte University Hospital: O.D. Pedersen, J. Kjoergaard; Roskilde Amtssygehuset: P. Fruergaard, T. Melchoir; Hvidovre Hospital: S. Lind Rasmussen; Koge Sygehus: K. Klarlund; Svendborg Sygehus: K. Egstrup; Bispebjerg Hospital: N. Gadsbøll, O.D. Pedersen; KAS Herlev: N. Keller. France — Hôpital Européen Georges Pompidou: J.-Y. Le Heuzey; Centre Cardiologique du Nord: O. Piot; Centre Hospitalier René Dubos: P. Jourdain. Germany — J.W. Goethe University Hospital: S.H. Hohnloser; II Med Abteilung des AK St. Georg: K.-H. Kuch; Universitätsklinikum Mannheim: M. Borggrefe. Israel — Hadassah Medical Center (Mont Scopus Campus): T. Weiss; Wolfson Medical Center: J. Rozenman; Barzilai Medical Center: L. Reisin; B'nai Zion Medical Center: E. Goldhammer; HaEmek Medical Center: T. Rozenfeld, L. Bloch; Soroka Medical Center: A. Katz; Sieff Hospital: A. Marmor; Hadassah Medical Center (Ein Karem Hospital): H. Lotan; Shaare Zedek Medical Center: D. Tzivoni; Hillel Yaffe Medical Center: M. Shochat. Italy — Ospedale di Circolo e Fondazione Macchi: J.A. Salerno Uriarte; Mater Domini Institute: T. Forzani. Puerto Rico — School of Medicine, University of Puerto Rico: M.R. Garcia-Palmieri. United States — Marshfield Medical Research Center: H. Vidaillet; Oregon Health Sciences University: M. Raitt; W.M.S. Middleton Memorial Veterans Affairs Hospital: P. Kosolcharoen; Earle A. Chiles Research Institute: F. McBaron; Montefiore Medical Center: E.C. Palma; Desert Cardiology Center: A. Rubin; Rhode Island Hospital–Lifespan Academic Center: A.E. Buxton; Veterans Affairs West Los Angeles Medical Center: B.N. Singh; Thoracic and Cardio Health Care Foundation: J. Ip; Geisinger Health System: R. Storm; Brigham and Women's Hospital: W. Stevenson; Stratton Veterans Affairs Medical Center: J. Sacco; University of Louisville: G. Bhat; Northwest Ohio Cardiology Consultants: N. Smiley; St. Luke's–Roosevelt Hospital Center: J. Steinberg; MedCentre: J. Bonet.
- References
References
1
Braunwald E . Shattuck Lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369
Full Text | Web of Science | Medline2
2002 Heart and stroke statistical update. Dallas: American Heart Association, 2002.
3
Nohria A ,Lewis E ,Stevenson LW . Medical management of advanced heart failure. JAMA 2002;287:628-640
CrossRef | Web of Science | Medline4
Moser DK ,Mann DL . Improving outcomes in heart failure: it's not unusual beyond usual care. Circulation 2002;105:2810-2812
CrossRef | Web of Science | Medline5
Maisel WH ,Stevenson LW . Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:Suppl:2D-8D
CrossRef | Web of Science | Medline6
Benjamin EJ ,Wolf PA ,D'Agostino RB ,Silbershatz H ,Kannel WB ,Levy D . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952
Web of Science | Medline7
Feinberg WM ,Blackshear JL ,Laupacis A ,Kronmal R ,Hart RG . Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-473
CrossRef | Web of Science | Medline8
Dries DL ,Exner DV ,Gersh BJ ,Domanski MJ ,Waclawiw MA ,Stevenson LV . Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703
CrossRef | Web of Science | Medline9
Bourassa MG ,Gurne O ,Bangdiwala SI , et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22:Suppl A:14A-19A
CrossRef | Web of Science | Medline10
Carson PE ,Johnson GR ,Dunkman WB ,Fletcher RD ,Farrell L ,Cohn JN . The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation 1993;87:Suppl VI:VI-10211
Middlekauff HR ,Stevenson WG ,Stevenson LW . Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991;84:40-48
Web of Science | Medline12
The CONSENSUS Trial Study Group
Full Text | Web of Science | Medline13
Doval HC ,Nul DR ,Grancelli HO ,Perrone SV ,Bortman GR ,Curiel R . Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498
CrossRef | Web of Science | Medline14
Deedwania PC ,Singh BN ,Ellenbogen K ,Fisher S ,Fletcher R ,Singh SN . Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98:2574-2579
Web of Science | Medline15
AF-CHF Trial Investigators
Web of Science | Medline16
Lehto M ,Snapinn S ,Dickstein K ,Swedberg K ,Nieminen MS . Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005;26:350-356
CrossRef | Web of Science | Medline17
Wang TJ ,Larson MG ,Levy D , et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925
CrossRef | Web of Science | Medline18
Mathew J ,Hunsberger S ,Fleg J ,McSherry F ,Williford W ,Yusuf S . Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-922
CrossRef | Web of Science | Medline19
Zareba W ,Steinberg JS ,McNitt S ,Daubert JP ,Piotrowicz K ,Moss AJ . Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm 2006;3:631-637
CrossRef | Web of Science | Medline20
Olsson LG ,Swedberg K ,Ducharme A , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004
CrossRef | Web of Science | Medline21
Gronefeld GC ,Hohnloser SH . Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003;8:107-113
CrossRef | Medline22
Naccarelli GW ,Hynes BJ ,Wolbrette DL , et al. Atrial fibrillation in heart failure: prognostic significance and management. J Cardiovasc Electrophysiol 2003;14:Suppl:S281-S286
CrossRef | Web of Science | Medline23
Ehrlich JR ,Nattel S ,Hohnloser SH . Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405
CrossRef | Web of Science | Medline24
Hynes BJ ,Luck JC ,Wolbrette DL , et al. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol 2003;18:32-38
CrossRef | Web of Science | Medline25
Coplen SE ,Antman EM ,Berlin JA ,Hewitt P ,Chalmers TC . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-1116[Erratum, Circulation 1991;83:714.]
CrossRef | Web of Science | Medline26
Flaker GC ,Blackshear JL ,McBride R ,Kronmal RA ,Halperin JL ,Hart RG . Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532
CrossRef | Web of Science | Medline27
Stevenson WG ,Stevenson LW ,Middlekauff HR , et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-1463[Erratum, J Am Coll Cardiol 1997;30:1902.]
CrossRef | Web of Science | Medline28
Hohnloser SH ,Kuck K-H ,Lilienthal J . Rhythm or rate control in atrial fibrillation -- Pharmacologic Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-1794
CrossRef | Web of Science | Medline29
Brignole M ,Menozzi C ,Gasparini M , et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002;23:892-900
CrossRef | Web of Science | Medline30
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Full Text | Web of Science | Medline31
Van Gelder IC ,Hagens VE ,Bosker HA , et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840
Full Text | Web of Science | Medline32
Carlsson J ,Miketic S ,Windeler J , et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-1696
CrossRef | Web of Science | Medline33
Opolski G ,Torbicki A ,Kosior DA , et al. Rate control vs rhythm control in patients with nonvalvular atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004;126:476-486
CrossRef | Web of Science | Medline34
Wyse DG . Rhythm versus rate control trials in atrial fibrillation. J Cardiovasc Electrophysiol 2003;14:Suppl:S35-S39
CrossRef | Web of Science | Medline35
Fuster V ,Ryden LE ,Cannom DS , et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354[Erratum, Circulation 2007;116(6):e138.]
CrossRef | Medline36
Zipes DP ,Camm AJ ,Borggrefe M , et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death -- executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and Heart Rhythm Society. J Am Coll Cardiol 2006;48:1064-1108
CrossRef | Web of Science37
Hogg K ,Swedberg K ,McMurray J . Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327
CrossRef | Web of Science | Medline38
Hsu L-F ,Jais P ,Sanders P , et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-2383
Full Text | Web of Science | Medline39
Stulak JM ,Dearani JA ,Daly RC ,Zehr KJ ,Sundt TM III ,Schaff HV . Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006;82:494-501
CrossRef | Web of Science | Medline40
Bardy GH ,Lee KL ,Mark DB , et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237[Erratum, N Engl J Med 2005;352:2146.]
Full Text | Web of Science | Medline
- Citing Articles (227)
Citing Articles
1
A. John Camm, Christian F. Camm, Irina Savelieva. (2012) Medical treatment of atrial fibrillation. Journal of Cardiovascular Medicine 13:2, 97-107
CrossRef2
R. Pisters, R. Nieuwlaat, M. H. Prins, J.-Y. Le Heuzey, A. P. Maggioni, A. J. Camm, H. J. G. M. Crijns, . (2012) Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace
CrossRef3
Stefan H. Hohnloser. (2012) Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation. Clinical Cardiology 35:S1, S28-S32
CrossRef4
Jeff S. Healey, Girish M. Nair. (2012) Does catheter ablation for atrial fibrillation increase or reduce neurological insult?. Current Opinion in Cardiology 27:1, 36-40
CrossRef5
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) Nuevas evidencias, nuevas controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad Europea de Cardiología. Revista Española de Cardiología 65:1, 7-13
CrossRef6
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Española de Cardiología (English Edition) 65:1, 7-13
CrossRef7
Chern-En Chiang, Shu Zhang, Hung Fat Tse, Wee Siong Teo, Razali Omar, Charn Sriratanasathavorn. (2012) Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. International Journal of Cardiology
CrossRef8
Babar Parvez, Nagesh Chopra, Shane Rowan, Joseph C. Vaglio, Raafia Muhammad, Dan M. Roden, Dawood Darbar. (2012) A Common β1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology 59:1, 49-56
CrossRef9
J. C. Caldwell, M. A. Mamas. (2012) Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship. Heart Failure Reviews 17:1, 27-33
CrossRef10
M. Gosch, R.E. Roller, B. Böhmdorfer, U. Benvenuti-Falger, B. Iglseder, M. Lechleitner, U. Sommeregger, P. Dovjak. (2012) Management und Therapie des Vorhofflimmerns beim geriatrischen Patienten. Zeitschrift für Gerontologie und Geriatrie 45:1, 55-68
CrossRef11
Daniel Caldeira, Cláudio David, Cristina Sampaio. (2012) Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Archives of Cardiovascular Diseases
CrossRef12
, Michael D. Ezekowitz, Rangadham Nagarakanti, Andrzej Lubinski, Olga Bandman, Daniel Canafax, David J. Ellis, Peter G. Milner, Margaret Ziola, Bernard Thibault, Stefan H. Hohnloser. (2011) A randomized trial of budiodarone in paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology
CrossRef13
J.- M. Davy, T. Tri Cung, F. Cransac, F. Massin, A. Tapiero, F. Roubille, J.- L. Pasquié. (2011) La fibrillation atriale permanente. Archives of Cardiovascular Diseases Supplements 3:3, 225-235
CrossRef14
Jonathan P. Piccini, James P. Daubert. (2011) Cryoablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology 32:3, 233-242
CrossRef15
Alexander Burashnikov, Charles Antzelevitch. (2011) Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacology & Therapeutics 132:3, 300-313
CrossRef16
Gregory YH Lip, Hung Fat Tse, Deirdre A Lane. (2011) Atrial fibrillation. The Lancet
CrossRef17
E. N. Simantirakis, E. P. Koutalas, P. E. Vardas. (2011) Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered?. Europace
CrossRef18
Pedram Kazemian, Gavin Oudit, Bodh I. Jugdutt. (2011) Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews
CrossRef19
Shaojie Chen, Ying Dong, Jinqi Fan, Yuehui Yin. (2011) Rate vs. rhythm control in patients with atrial fibrillation — An updated meta-analysis of 10 randomized controlled trials. International Journal of Cardiology 153:1, 96-98
CrossRef20
T. Nakano, K. Shimizu, O. Kawashima, M. Kamiyoshihara, T. Nagashima, T. Ibe, I. Takeyoshi. (2011) Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. Journal of Clinical Pharmacy and Therapeuticsno-no
CrossRef21
Alberto García-Castelo, Javier García-Seara, Fernando Otero-Raviña, Manuel Lado, Andrés Vizcaya, Juan M. Vidal, Ramón Lafuente, David Bouza, Pamela V. Lear, José R. González-Juanatey. (2011) Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study). International Journal of Cardiology 153:1, 68-73
CrossRef22
Jason R. Guertin, Marc Dorais, Paul Khairy, Luc Sauriol, Alexis Matteau, Frédéric Poulin, Mario Talajic, Denis Roy, Jacques LeLorier. (2011) Atrial Fibrillation: A Real-Life Observational Study in the Québec Population. Canadian Journal of Cardiology 27:6, 794-799
CrossRef23
Steven M. Markowitz. (2011) Rhythm Control for Atrial Fibrillation. Journal of the American College of Cardiology 58:19, 1986-1988
CrossRef24
John C Somberg. (2011) The Impact of Comorbidities on Stroke Prophylaxis Strategies in Atrial Fibrillation Patients. American Journal of Therapeutics 18:6, 510-517
CrossRef25
I. C. Van Gelder, L. M. Haegeli, A. Brandes, H. Heidbuchel, E. Aliot, J. Kautzner, L. Szumowski, L. Mont, J. Morgan, S. Willems, S. Themistoclakis, M. Gulizia, A. Elvan, M. D. Smit, P. Kirchhof. (2011) Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 13:11, 1517-1525
CrossRef26
Nikolaos Dagres, Christos Varounis, Thomas Gaspar, Christopher Piorkowski, Charlotte Eitel, Efstathios K. Iliodromitis, John P. Lekakis, Panayota Flevari, Eftihia Simeonidou, Loukianos S. Rallidis, Elias Tsougos, Gerhard Hindricks, Philipp Sommer, Maria Anastasiou-Nana. (2011) Catheter Ablation for Atrial Fibrillation in Patients With Left Ventricular Systolic Dysfunction. A Systematic Review and Meta-Analysis. Journal of Cardiac Failure 17:11, 964-970
CrossRef27
BRUNO ANDREA, GERHARD HINDRICKS. (2011) Impact of Catheter Ablation on Quality of Life in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiologyno-no
CrossRef28
G. C. M. Linssen, M. Rienstra, T. Jaarsma, A. A. Voors, I. C. van Gelder, H. L. Hillege, D. J. van Veldhuisen. (2011) Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. European Journal of Heart Failure 13:10, 1111-1120
CrossRef29
K. Wasmer, L. Eckardt. (2011) Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 13:10, 1368-1374
CrossRef30
Amir M. Nia, Natig Gassanov, Kristina M. Dahlem, Evren Caglayan, Martin Hellmich, Erland Erdmann, Fikret Er. (2011) Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clinical Research in Cardiology 100:10, 887-896
CrossRef31
K. Kaszala, K. A. Ellenbogen. (2011) Role of cardiac resynchronization therapy and atrioventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal 32:19, 2344-2346
CrossRef32
Alberto Conti, Erica Canuti, Yuri Mariannini, Maurizio Zanobetti, Francesca Innocenti, Barbara Paladini, Giuseppe Pepe, Luigi Padeletti, Gian Franco Gensini. (2011) Aggressive approach and outcome in patients presenting atrial fibrillation and hypertension. International Journal of Cardiology
CrossRef33
, Thomas Meinertz, Wilhelm Kirch, Ludger Rosin, David Pittrow, Stefan N. Willich, Paulus Kirchhof. (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clinical Research in Cardiology 100:10, 897-905
CrossRef34
Daniel Caldeira, Cláudio David, Cristina Sampaio. (2011) Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. European Journal of Internal Medicine 22:5, 448-455
CrossRef35
A. John Camm, Carina Blomström-Lundqvist, Paul Dorian, Stefan H. Hohnloser, Carlos A. Morillo, Pasquale Santangeli, Isabelle C. van Gelder, Erik Wissner, Paulus Kirchhof. 2011. Clinical Trials on Atrial Fibrillation/Future Perspectives. , 137-160.
CrossRef36
Valérie Henrard, Anique Ducharme, Paul Khairy, Alejandro Gisbert, Denis Roy, Sylvie Levesque, Mario Talajic, Bernard Thibault, Normand Racine, Michel White, Peter G. Guerra, Jean-Claude Tardif. (2011) Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: Insights from the AF-CHF echocardiographic sub-study. International Journal of Cardiology
CrossRef37
H. Almroth, T. Andersson, E. Fengsrud, L. Friberg, P. Linde, M. Rosenqvist, A. Englund. (2011) The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Journal of Internal Medicine 270:3, 281-290
CrossRef38
D. Petrač. (2011) Antiarrhythmic drugs for maintaining of sinus rhythm. Interventional Medicine and Applied Science 3:3, 116-119
CrossRef39
Bradley P. Knight, Jason T. Jacobson. (2011) Assessing patients for catheter ablation during hospitalization for acute heart failure. Heart Failure Reviews 16:5, 467-476
CrossRef40
Shinsuke Miyazaki, Ashok J. Shah, Daniel Scherr, Michel Haïssaguerre. (2011) Atrial fibrillation: Pathophysiology and current therapy. Annals of Medicine 43:6, 425-436
CrossRef41
Mihoko Kawabata, Kenzo Hirao, Hitoshi Hachiya, Kouji Higuchi, Yasuaki Tanaka, Atsuhiko Yagishita, Osamu Inaba, Mitsuaki Isobe. (2011) Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. Journal of Cardiology 58:2, 108-115
CrossRef42
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef43
C. Torp-Pedersen, H. J. G. M. Crijns, C. Gaudin, R. L. Page, S. J. Connolly, S. H. Hohnloser, . (2011) Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace 13:8, 1118-1126
CrossRef44
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef45
G. Boriani, M. Gasparini, M. Landolina, M. Lunati, A. Proclemer, G. Lonardi, S. Iacopino, W. Rahue, M. Biffi, P. DiStefano, A. Grammatico, M. Santini, . (2011) Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. European Journal of Heart Failure 13:8, 868-876
CrossRef46
T. JARED BUNCH, BRIAN G. CRANDALL, J. PETER WEISS, HEIDI T. MAY, TAMI L. BAIR, JEFFREY S. OSBORN, JEFFREY L. ANDERSON, JOSEPH B. MUHLESTEIN, BENJAMIN D. HORNE, DONALD L. LAPPE, JOHN D. DAY. (2011) Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 22:8, 839-845
CrossRef47
Mark S. Link, Derek V. Exner, Mark Anderson, Michael Ackerman, Amin Al-Ahmad, Bradley P. Knight, Steven M. Markowitz, Elizabeth S. Kaufman, David Haines, Samuel J. Asirvatham, David J. Callans, J. Paul Mounsey, Frank Bogun, Sanjiv M. Narayan, Andrew D. Krahn, Suneet Mittal, Jagmeet Singh, John D. Fisher, Sumeet S. Chugh. (2011) HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011. Heart Rhythm 8:8, 1340-1356
CrossRef48
D. George Wyse. (2011) Lenient Versus Strict Rate Control in Atrial Fibrillation. Journal of the American College of Cardiology 58:9, 950-952
CrossRef49
Eric TS Lim, Jonathan Yap, Chee Tang Chin. (2011) Current and emerging therapies for stroke prophylaxis in atrial fibrillation. Clinical Investigation 1:7, 1019-1037
CrossRef50
A. John Camm, Günter Breithardt, Harry Crijns, Paul Dorian, Peter Kowey, Jean-Yves Le Heuzey, Ihsen Merioua, Laurence Pedrazzini, Eric N. Prystowsky, Peter J. Schwartz, Christian Torp-Pedersen, William Weintraub. (2011) Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology 58:5, 493-501
CrossRef51
Jana Svetlichnaya, Liviu Klein. (2011) Atrial fibrillation in elderly patients with heart failure: convergence of two cardiovascular epidemics in the 21st Century. Expert Review of Cardiovascular Therapy 9:7, 903-912
CrossRef52
Carolyn J. Sachs, David Schriger. (2011) To Shock or Not to Shock: That is the Question; Is There an Answer?. Annals of Emergency Medicine 57:6, 694-702
CrossRef53
John Camm. (2011) Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. International Journal of Cardiology
CrossRef54
Ki-Hun Kim, Jin Oh Na, Gi-Byoung Nam, Eun-Sun Jin, HyungOh Choi, Sung-Hwan Kim, Kee-Joon Choi, You-Ho Kim. (2011) Effect of catheter ablation on the left ventricular mass index and other echocardiograph parameters in atrial fibrillation patients: comparison with antiarrhythmic drug treatment. Journal of Echocardiography 9:2, 51-58
CrossRef55
Gerald V. Naccarelli. (2011) Post-ATHENA and beyond. Journal of Interventional Cardiac Electrophysiology 31:1, 55-60
CrossRef56
Nikolaos Dagres, Philipp Sommer, Maria Anastasiou-Nana, Gerhard Hindricks. (2011) Treating arrhythmias: an expert opinion. Expert Opinion on Pharmacotherapy 12:9, 1359-1367
CrossRef57
Paul Dorian. (2011) “Show Me the Money”: The Cost of Atrial Fibrillation. Canadian Journal of Cardiology
CrossRef58
Alexandra Perez, Daniel R Touchette, Robert J DiDomenico, Thomas D Stamos, Surrey M Walton. (2011) Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Cost-Effectiveness Analysis. Pharmacotherapy 31:6, 552-565
CrossRef59
Alessandro Marinelli, Alessandro Capucci. (2011) Antiarrhythmic drugs for atrial fibrillation. Expert Opinion on Pharmacotherapy 12:8, 1201-1215
CrossRef60
T. Jared Bunch, Bernard J. Gersh. (2011) Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine 26:5, 531-537
CrossRef61
Hendrik Bonnemeier, Ralph F. Bosch, Annette Kohlhaußen, Ludger Rosin, Stefan N. Willich, David Pittrow, Wilhelm Kirch, for the MOVE Study Group. (2011) Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Current Medical Research and Opinion 27:5, 995-1003
CrossRef62
Jean L. Rouleau. (2011) New and Emerging Drugs and Device Therapies for Chronic Heart Failure in Patients With Systolic Ventricular Dysfunction. Canadian Journal of Cardiology 27:3, 296-301
CrossRef63
Laurent M Haegeli, Firat Duru. (2011) Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. Future Cardiology 7:3, 415-423
CrossRef64
Luisa Benito, Jordi Hoyo, Àngels Montroig, Berta Fornés, Guillem Fluxà, David Martí, Montserrat Pedrós, Antoni Sisó, Lluís Mont, Òscar Miró, Blanca Coll-Vinent. (2011) Estudio sobre los efectos adversos de los fármacos antiarrítmicos en pacientes con fibrilación auricular atendidos en un Centro de Atención Primaria. Medicina Clínica
CrossRef65
Kelly M. Smith, Jennifer G. Bekker, Tracy E. Macaulay. (2011) Strategies for the Management of Postoperative Atrial Fibrillation. Orthopedics 34:5, 377-382
CrossRef66
2011. Arrhythmias in Different Heart Diseases and Situations. , 360-385.
CrossRef67
2011. Active Supraventricular Arrhythmias. , 93-180.
CrossRef68
S. Muzzarelli, H. Stricker, O. Pfister, P. Foglia, G. Moschovitis, G. Mombelli, H. Brunner-La Rocca. (2011) Individual dosage of digoxin in patients with heart failure. QJM 104:4, 309-317
CrossRef69
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci. (2011) Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence. Clinical Investigation 1:4, 579-588
CrossRef70
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds. (2011) Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13:3, 329-345
CrossRef71
Alexander Burashnikov, Charles Antzelevitch. (2011) Advances in the Pharmacologic Management of Atrial Fibrillation. Cardiac Electrophysiology Clinics 3:1, 157-167
CrossRef72
I. Savelieva, N. Kakouros, A. Kourliouros, A. J. Camm. (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13:3, 308-328
CrossRef73
JAMES A. REIFFEL. (2011) Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. Pacing and Clinical Electrophysiology 34:2, 247-259
CrossRef74
E. Aliot, A. Capucci, H. J. Crijns, A. Goette, J. Tamargo. (2011) Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 13:2, 161-173
CrossRef75
Kenzo Hirao. (2011) Japanese Journal of Electrocardiology 31:2, 199-201
CrossRef76
Masaomi Chinushi, Kenichi Iijima. (2011) Rate Control Is a Better Initial Treatment for Patients With Atrial Fibrillation and Heart Failure. Circulation Journal 75:4, 970-978
CrossRef77
Shinichi Niwano. (2011) Japanese Journal of Electrocardiology 31:2, 202-204
CrossRef78
Gregory Giamouzis, Andreas Kalogeropoulos, Vasiliki Georgiopoulou, Sonjoy Laskar, Andrew L. Smith, Sandra Dunbar, Filippos Triposkiadis, Javed Butler. (2011) Hospitalization Epidemic in Patients With Heart Failure: Risk Factors, Risk Prediction, Knowledge Gaps, and Future Directions. Journal of Cardiac Failure 17:1, 54-75
CrossRef79
Selvakumar Velu, Gregory Y. H. Lip. (2011) What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. Advances in Therapy 28:1, 1-12
CrossRef80
Fabiana Lucà, Mark La Meir, Carmelo Massimiliano Rao, Orlando Parise, Ludovico Vasquez, Rocco Carella, Roberto Lorusso, Benedetto Daniela, Jos Maessen, Gian Franco Gensini, Sandro Gelsomino. (2011) Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand. Cardiology Research and Practice 2011, 1-10
CrossRef81
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy, Valentin Fuster, Lars E. Rydén, David S. Cannom, Jean-Yves Le Heuzey, Harry J. Crijns, James E. Lowe, Anne B. Curtis, S. Bertil Olsson, Kenneth A. Ellenbogen, Eric N. Prystowsky, Jonathan L. Halperin, Juan Luis Tamargo, G. Neal Kay, L. Samuel Wann. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Journal of the American College of Cardiology 57:2, 223-242
CrossRef82
Michelle D Schmiegelow, Ole D Pedersen, Lars Køber, Marie Seibæk, Steen Z Abildstrøm, Christian Torp-Pedersen. (2011) Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study. BMC Cardiovascular Disorders 11:1, 19
CrossRef83
Takashi Kurita, Koichiro Motoki, Ryobun Yasuoka, Takayoshi Hirota, Yuzuru Akaiwa, Yasuhito Kotake, Shunichi Miyazaki. (2011) Rhythm Control Should Be Better for the Management of Patients With Atrial Fibrillation and Heart Failure. Circulation Journal 75:4, 979-985
CrossRef84
Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Naoko Kumagai, Hideki Origasa, The J-RHYTHM Registry Investigators. (2011) Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation. Circulation Journal 75:6, 1328-1333
CrossRef85
Giovanni Botto, Giuseppe Boriani, Stefano Favale, Maurizio Landolina, Giulio Molon, Claudio Tondo, Mauro Biffi, Giuseppe Grandinetti, Paolo De Filippo, Giovanni Raciti, Luigi Padeletti. (2011) Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial. Trials 12:1, 44
CrossRef86
Laurent M. Haegeli, Firat Duru. (2011) Management of Patients with Atrial Fibrillation: Specific Considerations for the Old Age. Cardiology Research and Practice 2011, 1-8
CrossRef87
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Heart Rhythm 8:1, 157-176
CrossRef88
Mahito Noro, Shingo Kujime, Naoshi Ito, Yoshinari Enomoto, Keijirou Nakamura, Tsuyoshi Sakai, Takao Sakata, Kaoru Sugi. (2011) Cost Effectiveness of Radiofrequency Catheter Ablation vs. Medical Treatment for Atrial Fibrillation in Japan. Circulation Journal 75:8, 1860-1866
CrossRef89
P. Kirchhof, M. Nabauer, A. Gerth, T. Limbourg, T. Lewalter, A. Goette, K. Wegscheider, A. Treszl, T. Meinertz, M. Oeff, U. Ravens, G. Breithardt, G. Steinbeck, . (2011) Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thrombosis and Haemostasis 105:6, 1010-1023
CrossRef90
Tsuyoshi Shiga, Atsushi Suzuki, Miyoko Naganuma, Fumitaka Hosaka, Morio Shoda, Nobuhisa Hagiwara. (2011) Clinical Outcome in Patients With Paroxysmal or Persistent Atrial Fibrillation Receiving Bepridil. Circulation Journal 75:6, 1334-1342
CrossRef91
Hideo Mitamura. (2011) Japanese Journal of Electrocardiology 31:4, 346-355
CrossRef92
Shinichi Niwano. (2011) Japanese Journal of Electrocardiology 31:4, 387-393
CrossRef93
Carmelo Lafuente-Lafuente, Corinne Emery, Caroline Laurendeau, Francis Fagnani, Jean-François Bergmann. (2010) Long term treatment of atrial fibrillation in elderly patients: A decision analysis. International Journal of Cardiology
CrossRef94
A. John Camm. (2010) Calidad de vida en pacientes con fibrilación auricular. Revista Española de Cardiología 63:12, 1393-1395
CrossRef95
A. Leenhardt, G. Moubarak, A. Messali, F. Extramiana. (2010) La fibrillation atriale est-elle un marqueur indépendant de risque cardio-vasculaire ?. Annales de Cardiologie et d'Angéiologie 59, S14-S18
CrossRef96
Stephen B. Wilton, Adam Fundytus, William A. Ghali, George D. Veenhuyzen, F. Russell Quinn, L. Brent Mitchell, Michael D. Hill, Peter Faris, Derek V. Exner. (2010) Meta-Analysis of the Effectiveness and Safety of Catheter Ablation of Atrial Fibrillation in Patients With Versus Without Left Ventricular Systolic Dysfunction. The American Journal of Cardiology 106:9, 1284-1291
CrossRef97
Philip B. Adamson. 2010. Devices for Following Heart Failure Patients. , 235-254.
CrossRef98
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef99
Mark D. O'Neill, Matthew Wright, Pierre Jaïs, Sebastien Knecht, Isabelle Nault, Seiichiro Matsuo, Shinsuke Miyazaki, Andrej Pernat, Amir Jadidi, Frédéric Sacher, D. Wyn Davies, Jacques Clémenty, Michel Haïssaguerre, Mélèze Hocini. 2010. Treatment of Atrial Arrhythmias in Heart Failure Patients. , 217-234.
CrossRef100
Arnold Pinter, Paul Dorian. (2010) REVIEW: New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. Cardiovascular Therapeutics 28:5, 302-310
CrossRef101
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31:19, 2369-2429
CrossRef102
Ralph Weber, Hans-Christoph Diener, Christian Weimar. (2010) Prevention of cardioembolic stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 8:10, 1405-1415
CrossRef103
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:10, 1360-1420
CrossRef104
Ola O Oyetayo, Carrie E Rogers, Prudence O Hofmann. (2010) Dronedarone: A New Antiarrhythmic Agent. Pharmacotherapy 30:9, 904-915
CrossRef105
Sarah M. Schumacher, Jeffrey R. Martens. (2010) Ion channel trafficking: A new therapeutic horizon for atrial fibrillation. Heart Rhythm 7:9, 1309-1315
CrossRef106
A. Gil Núñez. (2010) Avances en la prevención de la isquemia cerebral por fibrilación auricular. Neurología 25:7, 401-408
CrossRef107
M. Nabauer, A. Gerth, P. Kirchhof, A. Goette, T. Limbourg, C. Sprenger, B. Hoffmann, S. Willems, N. Doll, A. Schuchert, M. Oeff, U. Ravens, T. Meinertz, G. Steinbeck, G. Breithardt. (2010) Register und Studien des Deutschen Kompetenznetzes Vorhofflimmern (AFNET). Herzschrittmachertherapie + Elektrophysiologie 21:3, 153-159
CrossRef108
Daniel E Hilleman, Aryan N Mooss. (2010) Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers. Pharmacotherapy 30:9, 867-871
CrossRef109
Leif Carlsson, Göran Duker, Ingemar Jacobson. (2010) New pharmacological targets and treatments for atrial fibrillation. Trends in Pharmacological Sciences 31:8, 364-371
CrossRef110
Stéphane Ederhy, Ghislaine Dufaitre, Louise Boyer-Chatenet, Catherine Meuleman, Emanuele Di Angelantonio, Sylvie Lang, Franck Boccara, Ariel Cohen. (2010) Should all patients with non-valvular atrial fibrillation be anticoagulated?. International Journal of Cardiology 143:1, 8-15
CrossRef111
Chee W Khoo, Hoong Sern Lim, Gregory YH Lip. (2010) Dronedarone: NICE enough?. Expert Review of Cardiovascular Therapy 8:8, 1049-1051
CrossRef112
David L. Gray. 2010. Vernakalant (Kynapid): An Investigational Drug for the Treatment of Atrial Fibrillation. , 159-173.
CrossRef113
David R. Vinson, Ted Hoehn, David J. Graber, Terry M. Williams. (2010) Managing Emergency Department Patients with Recent-onset Atrial Fibrillation. The Journal of Emergency Medicine
CrossRef114
Sandeep Arora, Farouk Mookadam, Komandoor Srivathsan. (2010) Interventional management of atrial fibrillation. Expert Review of Cardiovascular Therapy 8:7, 949-958
CrossRef115
T.A. Winkel, S.E. Hoeks, O. Schouten, U. Zeymer, T. Limbourg, I. Baumgartner, D.L. Bhatt, Ph.G. Steg, S. Goto, J. Röther, P.P. Cacoub, H.J.M. Verhagen, J.J. Bax, D. Poldermans. (2010) Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease: Data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. European Journal of Vascular and Endovascular Surgery 40:1, 9-16
CrossRef116
Edward C Li, John S Esterly, Shaunte Pohl, Shane D Scott, Brian F McBride. (2010) Drug-Induced QT-Interval Prolongation: Considerations for Clinicians. Pharmacotherapy 30:7, 684-701
CrossRef117
Alessandro Marinelli, Alessandro Rosi, Alessandro Capucci. (2010) Role of sotalol in rhythm control of atrial fibrillation. Therapy 7:4, 391-407
CrossRef118
J. Raunso, O. D. Pedersen, H. Dominguez, M. L. Hansen, J. E. Moller, J. Kjaergaard, C. Hassager, C. Torp-Pedersen, L. Kober, . (2010) Atrial fibrillation in heart failure is associated with an increased risk of death only in patients with ischaemic heart disease. European Journal of Heart Failure 12:7, 692-697
CrossRef119
Melissa H. Kong, Linda K. Shaw, Christopher O’Connor, Robert M. Califf, Michael A. Blazing, Sana M. Al-Khatib. (2010) Is Rhythm-Control Superior to Rate-Control in Patients with Atrial Fibrillation and Diastolic Heart Failure?. Annals of Noninvasive Electrocardiology 15:3, 209-217
CrossRef120
Angela L McClanahan, Anne B Curtis. (2010) Rate versus rhythm control in atrial fibrillation: no one-size-fits-all. Expert Review of Cardiovascular Therapy 8:7, 891-893
CrossRef121
Ashok J. Shah, Xingpeng Liu, Amir S. Jadidi, Michel Haïssaguerre. (2010) Early management of atrial fibrillation: from imaging to drugs to ablation. Nature Reviews Cardiology 7:6, 345-354
CrossRef122
Volker Wizemann, Lin Tong, Sudtida Satayathum, Alex Disney, Takashi Akiba, Rachel B Fissell, Peter G Kerr, Eric W Young, Bruce M Robinson. (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney International 77:12, 1098-1106
CrossRef123
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef124
Marcello Disertori, Federico Lombardi, Simona Barlera, Roberto Latini, Aldo P. Maggioni, Prisca Zeni, Giuseppe Di Pasquale, Franco Cosmi, Maria Grazia Franzosi. (2010) Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial. American Heart Journal 159:5, 857-863
CrossRef125
David Conen, Christine M. Albert. (2010) Sex Differences in Atrial Fibrillation and Its Complications. Current Cardiovascular Risk Reports 4:3, 237-243
CrossRef126
I. Nault, S. Miyazaki, A. Forclaz, M. Wright, A. Jadidi, P. Jais, M. Hocini, M. Haissaguerre. (2010) Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. European Heart Journal 31:9, 1046-1054
CrossRef127
Maya Guglin, Ren Chen, Anne B. Curtis. (2010) Sinus rhythm is associated with fewer heart failure symptoms: Insights from the AFFIRM trial. Heart Rhythm 7:5, 596-601
CrossRef128
C. A. Wasywich, A. J. Pope, J. Somaratne, K. K. Poppe, G. A. Whalley, R. N. Doughty. (2010) Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis. Internal Medicine Journal 40:5, 347-356
CrossRef129
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef130
M. Gasparini, J. S. Steinberg, A. Arshad, F. Regoli, P. Galimberti, A. Rosier, J. C. Daubert, C. Klersy, G. Kamath, C. Leclercq. (2010) Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. European Heart Journal 31:8, 976-983
CrossRef131
Mario Talajic, Paul Khairy, Sylvie Levesque, Stuart J. Connolly, Paul Dorian, Marc Dubuc, Peter G. Guerra, Stefan H. Hohnloser, Kerry L. Lee, Laurent Macle, Stanley Nattel, Ole D. Pedersen, Lynne Warner Stevenson, Bernard Thibault, Albert L. Waldo, D. George Wyse, Denis Roy. (2010) Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology 55:17, 1796-1802
CrossRef132
Dobromir Dobrev, Stanley Nattel. (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375:9721, 1212-1223
CrossRef133
Stefano Fumagalli, Francesca Tarantini, Niccolo Marchionni. (2010) Atrial fibrillation: still a benign condition in the elderly?. Aging Health 6:2, 207-209
CrossRef134
Bernd-Dieter Gonska. (2010) Atrial fibrillation—rate or rhythm control?. Clinical Research in Cardiology Supplements 5:S1, 11-15
CrossRef135
Marcos Daccarett, Johannes Brachmann, Martin Schmidt. (2010) New concepts in understanding antiarrhythmic effects. Clinical Research in Cardiology Supplements 5:S1, 42-46
CrossRef136
Alexander Burashnikov, Charles Antzelevitch. (2010) New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7:3, 139-148
CrossRef137
Prakash C. Deedwania, Joel A. Lardizabal. (2010) Atrial Fibrillation in Heart Failure: A Comprehensive Review. The American Journal of Medicine 123:3, 198-204
CrossRef138
Michael Kühne, David Conen. (2010) Atrial fibrillation in women. Therapy 7:2, 139-146
CrossRef139
DA Fitzmaurice. (2010) Is there a role for cardioversion in the management of atrial fibrillation?. Therapy 7:2, 159-162
CrossRef140
Bharat K Kantharia. (2010) Cardiac arrhythmias in congestive heart failure. Expert Review of Cardiovascular Therapy 8:2, 137-140
CrossRef141
Jan Menke, Lars Lüthje, Andreas Kastrup, Jörg Larsen. (2010) Thromboembolism in Atrial Fibrillation. The American Journal of Cardiology 105:4, 502-510
CrossRef142
A. Shotan, M. Garty, D. S. Blondhein, S. R. Meisel, B. S. Lewis, M. Shochat, E. Grossman, A. Porath, V. Boyko, R. Zimlichman, A. Caspi, S. Gottlieb, . (2010) Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from heart failure survey in Israel (HFSIS). European Heart Journal 31:3, 309-317
CrossRef143
JACQUES BILLETTE, RAFIK TADROS. (2010) Imminent Ganglionic Ventricular Rate Control During Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 21:2, 200-202
CrossRef144
W.H. Wilson Tang, Gary S. Francis. (2010) The Year in Heart Failure. Journal of the American College of Cardiology 55:7, 688-696
CrossRef145
Jeremy A. Schafer, Nicole K. Kjesbo, Patrick P. Gleason. (2010) Dronedarone: Current Evidence and Future Questions. Cardiovascular Therapeutics 28:1, 38-47
CrossRef146
T. De Potter, A. Berruezo, L. Mont, M. Matiello, D. Tamborero, C. Santibanez, B. Benito, N. Zamorano, J. Brugada. (2010) Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace 12:1, 24-29
CrossRef147
Atsushi Takahashi. (2010) Catheter Ablation Is Established as a Treatment Option for Atrial Fibrillation. Circulation Journal 74:9, 1972-1977
CrossRef148
Jens Seiler, William G. Stevenson. (2010) Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review 18:1, 38-50
CrossRef149
Sébastien Knecht, Stephen B. Wilton, Michel Haïssaguerre. (2010) The 2010 Update of the ESC Guidelines for the Management of Atrial Fibrillation. Circulation Journal 74:12, 2534-2537
CrossRef150
Manuel Martínez-Sellés, Tomás Datino, Óscar Díaz-Castro, Ramón López-Palop. (2010) Actualización en cardiología geriátrica. Revista Española de Cardiología 63, 17-28
CrossRef151
A. Gil Núñez. (2010) Advances in the Prevention of Cerebral Ischaemia Due to Atrial Fibrillation. Neurología (English Edition) 25:7, 401-408
CrossRef152
Andrew D. Choi, Khashayar Hematpour, Marrick Kukin, Suneet Mittal, Jonathan S. Steinberg. (2010) Ablation vs Medical Therapy in the Setting of Symptomatic Atrial Fibrillation and Left Ventricular Dysfunction. Congestive Heart Failure 16:1, 10-14
CrossRef153
M. Schmidt, M. Daccarett, J. Brachmann. (2010) Atrial fibrillation ablation in systolic heart failure patients: a promising tool?. Europace 12:1, 1-2
CrossRef154
Marcelle D. Smit, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder. (2010) Guidelines for Atrial Fibrillation in Heart Failure Need To Be Clarified. Journal of the American College of Cardiology 55:2, 167
CrossRef155
Jean-Benoît le Polain de Waroux, Mario Talajic, Paul Khairy, Peter G Guerra, Denis Roy, Bernard Thibault, Marc Dubuc, Laurent Macle. (2010) Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future. Future Cardiology 6:1, 51-66
CrossRef156
Jeffrey WH Fung, Cheuk-Man Yu. (2010) The 2010 Update of the ESC Guidelines for the Management of Atrial Fibrillation. Circulation Journal 74:12, 2538-2541
CrossRef157
Tatjana Potpara, Miodrag Grujic. (2010) Hundred years of atrial fibrillation: Current knowledge and perspectives. Srpski arhiv za celokupno lekarstvo 138:1-2, 98-104
CrossRef158
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. European Heart Journal 30:24, 2969-2980
CrossRef159
Ph. Mabo, D. Pavin, E. Donal. (2009) Contrôle du rythme sinusal ou contrôle de la fréquence ventriculaire ?. Annales de Cardiologie et d'Angéiologie 58, S31-S34
CrossRef160
Rakesh Gopinathannair, Renee M. Sullivan, Brian Olshansky. (2009) Tachycardia-mediated cardiomyopathy: Recognition and management. Current Heart Failure Reports 6:4, 257-264
CrossRef161
F. Anselme. (2009) Contrôler la fréquence ventriculaire ?. Annales de Cardiologie et d'Angéiologie 58, S35-S37
CrossRef162
Joseph D. Mishkin, Sherry J. Saxonhouse, Gregory W. Woo, Thomas A. Burkart, William M. Miles, Jamie B. Conti, Richard S. Schofield, Samuel F. Sears, Juan M. Aranda. (2009) Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge. Journal of the American College of Cardiology 54:22, 1993-2000
CrossRef163
Hessel F. Groenveld, Harry J.G.M. Crijns, Michiel Rienstra, Maarten P. Van den Berg, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder. (2009) Does intensity of rate control influence outcome in persistent atrial fibrillation?. American Heart Journal 158:5, 785-791
CrossRef164
Joachim R. Ehrlich, Stefan H. Hohnloser. (2009) Milestones in the management of atrial fibrillation. Heart Rhythm 6:11, S62-S67
CrossRef165
R. H. Falk, A. J. Camm. (2009) Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations. European Heart Journal 30:20, 2438-2440
CrossRef166
H. J.G.M. Crijns. (2009) Primary prevention of atrial fibrillation by statins: still unresolved?. European Heart Journal 30:19, 2302-2303
CrossRef167
Kapil Kumar, Peter J. Zimetbaum. (2009) New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future. Current Treatment Options in Cardiovascular Medicine 11:5, 373-380
CrossRef168
R. Pisters, C. B. de Vos, R. Dennert, H. J. Crijns. (2009) Undetected paroxysmal atrial fibrillation in chronic heart failure patients: is it clinically relevant to catch the atrial phantom?. Europace 11:10, 1257-1259
CrossRef169
Jonathan P. Piccini, Adrian F. Hernandez, Xin Zhao, Manesh R. Patel, William R. Lewis, Eric D. Peterson, Gregg C. Fonarow. (2009) Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology 54:14, 1280-1289
CrossRef170
Janet M. McComb. (2009) Rate control during atrial fibrillation achieved by chronic endocardial vagal stimulation: Proof of principle. Heart Rhythm 6:9, 1287-1288
CrossRef171
J. Kjekshus. (2009) Is there a heart rate paradox - demystification of the myths?. Journal of Internal Medicine 266:3, 242-247
CrossRef172
M. I. Ahmed, M. White, O. J. Ekundayo, T. E. Love, I. Aban, B. Liu, W. S. Aronow, A. Ahmed. (2009) A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. European Heart Journal 30:16, 2029-2037
CrossRef173
Paulus Kirchhof, Günter Breithardt, A. John Camm, Harry Crijns. (2009) “Zooming in” to new horizons: Conduction abnormalities and other research perspectives in atrial fibrillation. Heart Rhythm 6:8, 1118-1119
CrossRef174
MARK A. CRANDALL, BENJAMIN D. HORNE, JOHN D. DAY, JEFFREY L. ANDERSON, JOSEPH B. MUHLESTEIN, BRIAN G. CRANDALL, J. PETER WEISS, JEFFREY S. OSBORNE, DONALD L. LAPPÉ, T. JARED BUNCH. (2009) Atrial Fibrillation Significantly Increases Total Mortality and Stroke Risk Beyond that Conveyed by the CHADS2 Risk Factors. Pacing and Clinical Electrophysiology 32:8, 981-986
CrossRef175
JAMES A. REIFFEL. (2009) Cardioversion for Atrial Fibrillation: Treatment Options and Advances. Pacing and Clinical Electrophysiology 32:8, 1073-1084
CrossRef176
Rakesh Gopinathannair, Renee M. Sullivan, Brian Olshansky. (2009) Update on medical management of atrial fibrillation in the modern era. Heart Rhythm 6:8, S17-S22
CrossRef177
Sabine Telemaque, James D Marsh. (2009) Modification of cardiovascular ion channels by gene therapy. Expert Review of Cardiovascular Therapy 7:8, 939-953
CrossRef178
Samuel Lévy. (2009) Current atrial fibrillation guidelines and therapy algorithms: Are they adequate?. Journal of Interventional Cardiac Electrophysiology 25:2, 111-116
CrossRef179
Gregory M. Marcus, Edmund Keung, Melvin M. Scheinman. (2009) The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 54:9, 777-787
CrossRef180
M. A. Mamas, J. C. Caldwell, S. Chacko, C. J. Garratt, F. Fath-Ordoubadi, L. Neyses. (2009) A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. European Journal of Heart Failure 11:7, 676-683
CrossRef181
Nikolaos Dagres, Christos Varounis, Panayota Flevari, Christopher Piorkowski, Kerstin Bode, Loukianos S. Rallidis, Elias Tsougos, Dionyssios Leftheriotis, Philipp Sommer, Gerhard Hindricks, Dimitrios Th. Kremastinos. (2009) Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials. American Heart Journal 158:1, 15-20
CrossRef182
KAPIL KUMAR, BRUCE D. NEARING, MARCELO CARVAS, BRUNO C.G. NASCIMENTO, MARIANA ACAR, LUIZ BELARDINELLI, RICHARD L. VERRIER. (2009) Ranolazine Exerts Potent Effects on Atrial Electrical Properties and Abbreviates Atrial Fibrillation Duration in the Intact Porcine Heart. Journal of Cardiovascular Electrophysiology 20:7, 796-802
CrossRef183
Marcelle D Smit, Isabelle C Van Gelder. (2009) Upstream therapy of atrial fibrillation. Expert Review of Cardiovascular Therapy 7:7, 763-778
CrossRef184
S. S. Andersen, M. L. Hansen, G. H. Gislason, T. K. Schramm, F. Folke, E. Fosbol, S. Z. Abildstrom, M. Madsen, L. Kober, C. Torp-Pedersen. (2009) Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 11:7, 886-891
CrossRef185
Dimpi Patel, Andrea Natale, Luigi Di Biase, J David Burkhardt, Yan Wang, Javier E Sanchez, Rodney P Horton, Mohammed Khan. (2009) Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. Expert Review of Cardiovascular Therapy 7:7, 779-787
CrossRef186
Alexander Burashnikov, Charles Antzelevitch. (2009) New Pharmacological Strategies for the Treatment of Atrial Fibrillation. Annals of Noninvasive Electrocardiology 14:3, 290-300
CrossRef187
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11:7, 860-885
CrossRef188
J.-Y. Le Heuzey. (2009) The risk of antiarrhythmic drugs in atrial fibrillation: 20 years of controversies. Europace 11:7, 840-841
CrossRef189
P. Mabo, A. Leenhardt, P. Jaillon, S. Kacet, F. Aubin, I. Denjoy, J.-Y. Le Heuzey. (2009) Fibrillation atriale, description de la prise en charge par les cardiologues, étude observationnelle. Résultats de l’étude Factuel. Annales de Cardiologie et d'Angéiologie 58:3, 151-158
CrossRef190
Suresh Krishnamoorthy, Gregory YH Lip. (2009) Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Review of Cardiovascular Therapy 7:5, 473-481
CrossRef191
Stefan H. Hohnloser. (2009) Nuevas perspectivas farmacológicas en pacientes con fibrilación auricular: el ensayo ATHENA. Revista Española de Cardiología 62:5, 479-481
CrossRef192
Wilbert S. Aronow. (2009) Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD. American Journal of Kidney Diseases 53:4, 701-710
CrossRef193
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef194
Bruce M. Psaty, Sarah E. Psaty. (2009) FLECAINIDE TOXICITY IN AN OLDER ADULT. Journal of the American Geriatrics Society 57:4, 751-753
CrossRef195
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef196
Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
CrossRef197
Ganesh S. Kamath, Delia Cotiga, Jayanthi N. Koneru, Aysha Arshad, Walter Pierce, Emad F. Aziz, Anisha Mandava, Suneet Mittal, Jonathan S. Steinberg. (2009) The Utility of 12-Lead Holter Monitoring in Patients With Permanent Atrial Fibrillation for the Identification of Nonresponders After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology 53:12, 1050-1055
CrossRef198
Jean-Yves Le Heuzey, Éloi Marijon, Akli Otmani, Antoine Lepillier, Xavier Waintraub, Thomas Lavergne, Maurice Pornin. (2009) Traiter la fibrillation atriale dans l'insuffisance cardiaque. Thérapie 64:2, 115-119
CrossRef199
Wanwarang Wongcharoen, Shih-Ann Chen. (2009) Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation. Expert Review of Cardiovascular Therapy 7:3, 311-322
CrossRef200
J. F. Doyle, K. M. Ho. (2009) Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clinic Proceedings 84:3, 234-242
CrossRef201
J. Horowitz, W. J. Remme, C. Torp-Pedersen. (2009) Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE. Cardiovascular Drugs and Therapy 23:1, 25-29
CrossRef202
David B Brieger, S Ben Freedman. (2009) Delirium cordis: can we predict the onset of atrial fibrillation?. The Lancet 373:9665, 698-700
CrossRef203
Alessandro Capucci. (2009) Atrial fibrillation and congestive heart failure: should we aim to control the heart's rate or its rhythm?. Nature Clinical Practice Cardiovascular Medicine 6:1, 6-7
CrossRef204
T Ben Morrison, T Jared Bunch, Bernard J Gersh. (2009) Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nature Clinical Practice Cardiovascular Medicine 6:1, 46-56
CrossRef205
Paul G Novak. (2009) Effectiveness of catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation. Current Opinion in Cardiology 24:1, 9-17
CrossRef206
David Waldenhjort, Märit Mejhert, Magnus Edner, Mårten Rosenqvist, Hans Persson. (2009) Congestive heart failure with and without atrial fibrillation – different patient populations?. Scandinavian Cardiovascular Journal 43:3, 169-175
CrossRef207
Manuel Martínez-Sellés, Ramón López-Palop, Tomás Datino, Camino Bañuelos. (2009) Actualización en cardiología geriátrica. Revista Española de Cardiología 62, 53-66
CrossRef208
Denis Roy, Mario Talajic, Marc Dubuc, Bernard Thibault, Peter Guerra, Laurent Macle, Paul Khairy. (2009) Atrial fibrillation and congestive heart failure. Current Opinion in Cardiology 24:1, 29-34
CrossRef209
Sanae Hamaguchi, Hisashi Yokoshiki, Shintaro Kinugawa, Miyuki Tsuchihashi-Makaya, Takashi Yokota, Akira Takeshita, Hiroyuki Tsutsui, The JCARE-CARD Investigators. (2009) Effects of Atrial Fibrillation on Long-Term Outcomes in Patients Hospitalized for Heart Failure in Japan. Circulation Journal 73:11, 2084-2090
CrossRef210
Hideo Mitamura. (2009) Japanese Journal of Electrocardiology 29:3, 239-241
CrossRef211
Laurent Fauchier, Caroline Grimard, Bertrand Pierre, Emilie Nonin, Laurent Gorin, Bruno Rauzy, Pierre Cosnay, Dominique Babuty, Bernard Charbonnier. (2009) Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure. The American Journal of Cardiology 103:2, 248-254
CrossRef212
Joachim R Ehrlich, Stanley Nattel. (2009) Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology 24:1, 50-55
CrossRef213
A. Bajpai, I. Savelieva, A. J. Camm. (2008) Treatment of atrial fibrillation. British Medical Bulletin 88:1, 75-94
CrossRef214
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef215
Jörn Schmitt, Joachim R. Ehrlich, Stefan H. Hohnloser. (2008) New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation. Herz Kardiovaskuläre Erkrankungen 33:8, 562-567
CrossRef216
Florian Straube, Uwe Dorwarth, Sabine Janko, Ellen Hoffmann. (2008) Frequenzkontrolle versus Rhythmuskontrolle mit und ohne Herzinsuffizienz. Herz Kardiovaskuläre Erkrankungen 33:8, 568-579
CrossRef217
Steen D. Kristensen, Helmut Baumgartner, Barbara Casadei, Helmut Drexler, Eric Eeckhout, Gerasimos Filippatos, Keith A.A. Fox, Joep Perk, Luc A. Pierard, Don Poldermans, Heribert Schunkert, Panos E. Vardas, Ernst E. van der Wall, Kim Fox, Jeroen J. Bax. (2008) Highlights of the 2008 Scientific Sessions of the European Society of Cardiology. Journal of the American College of Cardiology 52:24, 2032-2042
CrossRef218
C. W. Israel. (2008) Optimizing the treatment of atrial fibrillation: contributions by remote monitoring. Europace 11:1, 7-8
CrossRef219
W.H. Wilson Tang, Gary S. Francis. (2008) The Year in Heart Failure. Journal of the American College of Cardiology 52:20, 1671-1678
CrossRef220
Peter Weeke, Charlotte Andersson, Bente Brendorp, Christian Torp-Pedersen. (2008) Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety. Future Cardiology 4:6, 559-567
CrossRef221
(2008) Rhythm Control versus Rate Control for Atrial Fibrillation. New England Journal of Medicine 359:14, 1522-1522
Full Text222
O. Jolobe. (2008) Stroke risk might be specifically correlated with the burden of paroxysmal atrial fibrillation. Journal of Internal Medicine 264:4, 401-401
CrossRef223
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef224
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:9, 770-776
CrossRef225
Wilbert S. Aronow. (2008) Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review 16:5, 230-239
CrossRef226
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:8, 676-683
CrossRef227
Cain, Michael E., Curtis, Anne B., . (2008) Rhythm Control in Atrial Fibrillation — One Setback after Another. New England Journal of Medicine 358:25, 2725-2727
Full Text
- Letters
